4-1BB agonism: adding the accelerator to cancer immunotherapy
The success of checkpoint inhibitors has validated immunomodulatory agents as a valuable class of anticancer therapeutics. A promising co-stimulatory immunologic target is 4-1BB, or CD137, a member of the tumor necrosis factor receptor superfamily. Ligation of 4-1BB induces an activating signal in C...
| Main Authors: | , , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
Springer Berlin Heidelberg
2016
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5035667/ |